15-Jul-2026
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
Globe Newswire (Tue, 19-May 4:45 PM ET)
DERM Delivers 21% Revenue Growth, Strong Cash Position, and Expanding Emrosi® Momentum in Q1 2026
Market Chameleon (Thu, 14-May 6:02 AM ET)
Globe Newswire (Wed, 13-May 4:01 PM ET)
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Globe Newswire (Wed, 6-May 4:01 PM ET)
PRNewswire (Thu, 30-Apr 10:40 PM ET)
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi
Globe Newswire (Tue, 21-Apr 8:30 AM ET)
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Journey Medical trades on the NASDAQ stock market under the symbol DERM.
As of July 15, 2026, DERM stock price climbed to $7.27 with 146,175 million shares trading.
DERM has a beta of 2.10, meaning it tends to be more sensitive to market movements. DERM has a correlation of 0.17 to the broad based SPY ETF.
DERM has a market cap of $200.18 million. This is considered a Small Cap stock.
Last quarter Journey Medical reported $16 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $564,464 and met earnings estimates .
In the last 3 years, DERM traded as high as $9.56 and as low as $1.60.
The top ETF exchange traded funds that DERM belongs to (by Net Assets): VTI, VXF, VTWO, IWC, QQQS.
DERM has underperformed the market in the last year with a return of -1.9%, while SPY returned +22.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in DERM shares. However, DERM has outperformed the market in the last 3 month and 2 week periods, returning +38.2% and +2.7%, while SPY returned +9.0% and +1.1%, respectively. This indicates DERM has been having a stronger performance recently.
DERM support price is $6.79 and resistance is $7.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DERM shares will trade within this expected range on the day.
